World COPD Day

Posted by Tracy Hendershott on Nov 21, 2018 9:00:00 AM
Tracy Hendershott
Find me on:

World Chronic Obstructive Pulmonary Disease (COPD) Day is organized by the Gloobal Initiative for Chronic Obstructive Lung Disease (GOLD) in collaboration with health care professionals and COPD patient groups throughout the world. World COPD Day is celebrated on November 15th, 2018, and it's aim is to raise awareness about the disease and improve outcomes throughout the world.

The 2018 theme for World COPD Day is "Never Too Early, Never Too Late."

Stethoscope with blue doctor coat on wooden table with shallow DOF evenly matched and background

World Prematurity Day at Eurofins Central Laboratory

Globally, it is estimated that 3.17 million deaths were caused by Chronic Obstructive Pulmonary Disease (COPD) in 2015 (that is, 5 percent of all deaths worldwide that year). With these significant statistics, it is not surprising that there are over 3,200 COPD registrations across varying intervention methodologies; behavioural studies, device protocols and Biopharmaceutical clinical trials.

While COPD is not currently curable, treatment can relieve symptoms, improve quality-of-life and reduce the risk of death. The challenges within the drug development arena, are the lack of established diagnostic and early indication biomarkers in a laboratory setting. While spirometry is the current gold standard for reliable diagnosis, it is a better indicator of disease severity, than disease activity.

Being a multicomponent indication, there are numerous biological pathways currently being explored in inflammation (fibrinogen, IL-6, IL-8, CRP), extracellular matrix markers (MMP-8, MMP-9, SP-D, CC-16, CCL-18), sputum (TNF-α, IL-β, IL-6, IL-1α, IL-1β, IL-17A, IL-18, CXCL1, CXCL8,  CXCL9, CXCL10, CXCL11, CCL2, CCL5) and broncoalveolar lavage (BAL) specimens (CD-4, CD-8, HNP, SP-D, PRH1, PRH2, CC10).

These exploratory biomarkers are being investigated in proof of concept regulatory validation, it is important to partner with a laboratory organization that is able to simultaneously work in GCP and GLP environment for bioanalytical method biomarker validations, to include analytical performance validation (sensitivity, specificity, robustness, accuracy, reproducibility). 

Eurofins Central Laboratory provides the BioPharma industry just that solution with both GCP (safety and efficacy) and GLP (advance biomarker validation) at the same laboratory location. This provides value-added qualities to your clinical trial conducted by increasing specimen security, eliminating unnecessary specimen transport fees and reducing multiple vendor management administrative burdens. 

Please reach out to our Scientific Team here and we can begin exploring the most scientifically valid and economically sound solutions for your COPD/Asthma clinical research.



G. Paone, V. Leone, V. Conti, L. De Marchis, E. Ialleni, C. Graziani, M. Salducci, M. Ramaccia, G. Munafò
Blood and sputum biomarkers in COPD and asthma: a review Eur Rev Med Pharmacol Sci Year: 2016 Vol. 20 - N. 4 Pages: 698-708 DOI: 
Link to CC license: 
No revisions have been made to the original article.



Tags: Central Laboratory, Clinical Trial, Drug Development